What's Happening?
PureTech Health has announced the publication of results from its Phase 2b ELEVATE IPF trial in The American Journal of Respiratory and Critical Care Medicine. The trial evaluated deupirfenidone for treating idiopathic pulmonary fibrosis (IPF), a rare
and fatal lung disease. The study showed that deupirfenidone significantly slowed lung function decline compared to placebo, with an adjusted mean forced vital capacity (FVC) difference of 91 mL. This trial is the first industry-sponsored IPF study to include a current standard-of-care treatment as an active comparator, enhancing the interpretation of efficacy and safety findings. Celea Therapeutics, a PureTech-founded entity, plans to initiate a Phase 3 SURPASS-IPF trial in 2026, aiming to test deupirfenidone against pirfenidone in a head-to-head study. The results suggest that deupirfenidone may offer greater preservation of lung function than existing therapies, potentially transforming treatment approaches for IPF patients.
Why It's Important?
The publication of the ELEVATE IPF trial results is significant as it highlights a potential new standard of care for idiopathic pulmonary fibrosis, a disease with limited treatment options and poor prognosis. The trial's findings suggest that deupirfenidone could offer improved lung function preservation, which is crucial for enhancing the quality of life and survival rates of IPF patients. If the Phase 3 trial confirms these results, it could lead to a shift in treatment paradigms, offering hope to patients and healthcare providers dealing with this challenging condition. The inclusion of a standard-of-care treatment as a comparator in the trial also provides robust data that could influence future clinical practices and regulatory approvals.
What's Next?
Celea Therapeutics is preparing to launch the Phase 3 SURPASS-IPF trial in the first half of 2026, which will further evaluate deupirfenidone's efficacy compared to pirfenidone. This trial aims to confirm the Phase 2b findings and establish deupirfenidone as a superior treatment option for IPF. The success of this trial could lead to regulatory approval and widespread adoption of deupirfenidone, potentially improving outcomes for IPF patients. Additionally, ongoing research and development efforts may expand the use of deupirfenidone to other fibrotic conditions, broadening its impact in respiratory medicine.
